CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10367720" target="_blank" >RIV/00216208:11140/18:10367720 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/18:10367720

Výsledek na webu

<a href="http://dx.doi.org/10.21873/anticanres.12245" target="_blank" >http://dx.doi.org/10.21873/anticanres.12245</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12245" target="_blank" >10.21873/anticanres.12245</a>

Jazyk výsledku

angličtina

Název v původním jazyce

CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer

Popis výsledku v původním jazyce

Aim: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery. Patients and Methods: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 712 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status. Results: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p&lt;0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined. Conclusion: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence.

Název v anglickém jazyce

CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer

Popis výsledku anglicky

Aim: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery. Patients and Methods: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 712 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status. Results: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p&lt;0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined. Conclusion: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

5

Strana od-do

465-469

Kód UT WoS článku

000419130100062

EID výsledku v databázi Scopus

2-s2.0-85039801076